Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash & Equivalents (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Cash & Equivalents for 9 consecutive years, with $559.5 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 29.44% year-over-year to $559.5 million; the TTM value through Mar 2026 reached $559.5 million, down 29.44%, while the annual FY2025 figure was $628.1 million, 5.53% down from the prior year.
  • Cash & Equivalents hit $559.5 million in Q1 2026 for Bicycle Therapeutics, down from $628.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $961.4 million in Q2 2024 and bottomed at $100.0 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $543.0 million, with a median of $559.5 million recorded in 2026.
  • Year-over-year, Cash & Equivalents plummeted 48.95% in 2022 and then soared 193.81% in 2023.
  • Bicycle Therapeutics' Cash & Equivalents stood at $339.2 million in 2022, then surged by 55.22% to $526.4 million in 2023, then rose by 26.31% to $664.9 million in 2024, then dropped by 5.53% to $628.1 million in 2025, then fell by 10.92% to $559.5 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $559.5 million, $628.1 million, and $648.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.